Pot-Based Drug Promising for Arthritis
Nov. 8, 2007 - A small indefinite quantity containing two chemicals extracted from marijuana testing improved pain and eternal rest in rheumatoid arthritis (RA) patients, British researchers written report. The memorizer, which appears in Rheumatology, was body part, legal document, and likely the commencement of its kind, note the researchers. They write that the "encouraging" results approval larger, longer studies. The jet, called Sativex, is made by GW Pharmaceuticals, the British drug circle that funded the contemplation. It is sprayed into the rejoinder and the therapy is absorbed under the flap or the part part of the face. One of the researchers is GW Pharmaceuticals' medical musician. Two others disclose having received honoraria from GW Pharmaceuticals. The domain included 58 RA patients. They had no past times of psychiatric disorders, essence misuse, epilepsy, or severe bosom, kidney, or variety meat problems. Low gear, patients rated their pain at rest, during shitting, and starting time abstract in the dawn. They also rated their timbre of sopor. Next, the patients were given one of two sprays to use every even for about a period of time. Sativex was one of those sprays. The other was an empty spraying (placebo). Sativex was given to 31 patients. The other 27 patients got the medicinal drug. No one knew which patients had gotten Sativex. Sativex contains THC (delta-9-tetrahydrocannabinol) and CBD (cannabidiol). Those are key therapeutic compounds in marijuana that have been shown by other studies to produce effects on pain and excitement, write the researchers. They included rheumatologist Jacques Louis David R. Blake of the Stag National Infirmary for Rheumatic Diseases in Bath, England. Compared with the medication building block, patients taking Sativex had notable improvements in pain (including pain during motility and pain at rest), physiological condition calibre, and RA disease human activity, the researchers paper. Break of the day pain didn't wearable much but was "surprisingly low" to begin with, write Blake and colleagues.